Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Trial of Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors (DSRCT) Expressing PDGF-R

NCT00417807 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00417807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00417807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Trial of Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors (DSRCT) Expressing PDGF-R
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2005
Completion date
Not reported
Enrollment
9 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

refractory desmoplastic small round cell tumors